FeRx targets MCT (Magnetic Targeted Carrier) method at GI (gastrointestinal) diseases:
This article was originally published in Clinica
Preclinical results have suggested that FeRx' magnetic field-based drug delivery technique is a feasible method for delivering compounds to the gastrointestinal (GI) tract, the San Diego, California firm has reported. The Magnetic Targeted Carrier (MTC) technique may help treat GI diseases, such as inflammatory bowl disease and cancerous tumours of the oesophagus, stomach and colon, via an intra-luminal route of administration. FeRx has previously demonstrated delivery of MTCs via intra-arterial and intra-vesical routes of administration, possibly leading to the treatment of a variety of solid tumours, including those of the liver and bladder (see Clinica No 1004, p 24).
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.